Business
ABL Diagnostics: Availability of the 2025 Annual Financial Report
WOIPPY, France, May 07, 2026--Regulatory News: ABL Diagnostics (Paris:ABLD) announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorité des marchés financiers (AMF).
About this update from Abl Diagnostics Sa
WOIPPY, France, May 07, 2026 --( BUSINESS WIRE )--Regulatory News: ABL Diagnostics (Paris:ABLD) announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorité des marchés financiers (AMF). The report can be consulted on the ABL Diagnostics website: https://www.abldiagnostics.com under the section "Newsroom – Legal & Financial News". The Board of Directors, which met on April 30, 2025, approved the annual financial statements and decided to convene the shareholders to an Ordinary and Extraordinary General Meeting on June 30, 2026 at 11:00 a.m. at the offices of the law firm De Gaulle Fleurance & Associés, located at 9 rue Boissy d’Anglas, 75008 Paris. About ABL Diagnostics (ABLD) ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers: ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion. ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. An expanding portfolio of microbiology products: Integrated Solutions ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology. View source version on businesswire.com: https://www.businesswire.com/news/home/20260507441661/en/ Contacts ABL Diagnostics SA Société anonyme au capital de 1 611 465,60 euros Headquarters : 72C route de Thionville - 57140 WOIPPY 552 064 933 R.C.S. METZ Tel : +33 (0)7 83 64 68 50 Email : [email protected] https://www.abldiagnostics.com/
View stock analysis, news, and events for Abl Diagnostics Sa